Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Blueprint Medicines Corp
(NQ:
BPMC
)
93.19
+0.61 (+0.66%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Blueprint Medicines Corp
< Previous
1
2
3
4
5
6
Next >
Why Blueprint Medicines Stock Soared Today
October 26, 2023
The precision-treatment company saw stronger-than-expected sales in its first full quarter following the launch of Ayvakit.
Via
The Motley Fool
12 Health Care Stocks Moving In Thursday's Intraday Session
October 26, 2023
Via
Benzinga
Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
October 26, 2023
Gainers
Via
Benzinga
Blueprint Medicines's Earnings: A Preview
October 25, 2023
Via
Benzinga
Analyst Ratings for Blueprint Medicines
August 21, 2023
Via
Benzinga
IBM, ServiceNow, Lennox, Morningstar And Other Big Stocks Moving Higher On Thursday
October 26, 2023
U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking the trend and recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Unpacking Blueprint Medicines' Ayvakit's Bright Future: Insights From Latest Physician Survey On Sales Predictions
August 21, 2023
Needham slightly increased the price target for Blueprint Medicines Corp (NASDAQ: BPMC) from $65 to $66
Via
Benzinga
What 15 Analyst Ratings Have To Say About Blueprint Medicines
August 02, 2023
Via
Benzinga
Why Shares of Blueprint Medicines Are Falling Wednesday
August 02, 2023
The company had generally improved earnings.
Via
The Motley Fool
A Preview Of Blueprint Medicines's Earnings
August 01, 2023
Via
Benzinga
Analyst Ratings for Blueprint Medicines
July 14, 2023
Via
Benzinga
What Will AbbVie Buy Next?
June 28, 2023
Two mid-cap drugmakers stand out as logical targets for AbbVie.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
July 31, 2023
Via
Benzinga
3 Biotech Stocks Using AI to Change Healthcare Forever
July 14, 2023
These three biotech firms are leveraging artificial intelligence to revolutionize therapeutics and make disease a thing of the past.
Via
InvestorPlace
Analyst Expectations for Blueprint Medicines's Future
June 14, 2023
Via
Benzinga
FDA OKs Blueprint Medicines' Blood Disorder Drug As First Treatment For SM Patients
May 23, 2023
The U.S.
Via
Benzinga
Analyst Expectations for Blueprint Medicines's Future
May 23, 2023
Via
Benzinga
Blueprint Medicines's Return On Capital Employed Overview
May 15, 2023
Via
Benzinga
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
July 01, 2023
Via
Talk Markets
ETF Returns: Mid-Cap Winners And Losers
June 28, 2023
We performed a screening of mid-cap ETFs - defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns on...
Via
Benzinga
3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon
June 12, 2023
These three small cap drug companies could become gold or lead depending on the outcomes of their clinical trials.
Via
InvestorPlace
EPAM Systems, Amyris, Blueprint Medicines And Other Big Stocks Moving Lower On Monday
June 05, 2023
U.S. stocks traded mixed, with the Dow Jones dropping around 100 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Analyst Ratings for Blueprint Medicines
May 05, 2023
Via
Benzinga
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 05, 2023
Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 5, 2023
June 05, 2023
Via
Benzinga
US Stocks Mixed; SAIC Posts Upbeat Results
June 05, 2023
U.S. stocks traded mixed this morning, with Dow Jones dropping around 20 points on Monday. Following the market opening Monday, the Dow traded down 0.06% to 33,740.98 while the NASDAQ rose 0.08% to...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
June 05, 2023
Via
Benzinga
Meta Platforms To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Monday
June 05, 2023
BMO Capital boosted the price target for Equity Residential (NYSE: EQR) from $60 to $64. BMO Capital analyst John Kim upgraded the stock from Underperform to Market Perform. Equity Residential shares...
Via
Benzinga
This Biotech Could Soon Go Parabolic, But Should You Buy It?
June 04, 2023
Its situation is neither as good nor as bad as it might seem at first glance.
Via
The Motley Fool
Blueprint Medicines Earns Higher Price Targets Post FDA Approval: Analysts Optimistic on Ayvakit's Future
May 23, 2023
Shares of Blueprint Medicines Corporation (NASDAQ: BPMC) after it received FDA approval for its Ayvakit (avapritinib) as the first, only treatment for
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.